Dr Reddy's Lab falls after declaring poor Q4 result

Dr Reddy's Laboratories fell 1.48% to Rs 2,679 at 13:52 IST on BSE after consolidated net profit declined 15.64% to Rs 481.6 crore on 0.01% growth in total income to Rs 3503.53 crore in Q4 March 2014 over Q4 March 2013.

The company announced Q4 result during trading hours today, 13 May 2014.

Meanwhile, the S&P BSE Sensex was up 341.66 points or 1.45% at 23,892.58

On BSE, so far 39,365 shares were traded in the counter as against average daily volume of 29,023 shares in the past one quarter.

The stock hit a high of Rs 2,743.05 and a low of Rs 2,635.35 so far during the day. The stock had hit a record high of Rs 2,939.80 on 28 February 2014. The stock had hit a 52-week low of Rs 2,012 on 21 May 2013.

The stock had outperformed the market over the past one month till 12 May 2014, rising 5.8% compared with 4.07% rise in the Sensex. The scrip, however, underperformed the market in past one quarter, gaining 3.95% as against Sensex's 15.17% rise.

The large-cap company has equity capital of Rs 85.05 crore. Face value per share is Rs 5.

Dr Reddy's Laboratories is an integrated global pharmaceutical company. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products. Dr. Reddy's offers a portfolio of products and services including active pharmaceutical ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Powered by Capital Market - Live News